医学
急性呼吸窘迫综合征
低氧血症
呼吸衰竭
重症监护医学
急性呼吸窘迫
人口
麻醉
肺
内科学
环境卫生
作者
Elizabeth Levy,John P. Reilly
标识
DOI:10.1016/j.ccc.2023.12.002
摘要
Acute respiratory failure relies on supportive care using non-invasive and invasive oxygen and ventilatory support. Pharmacologic therapies for the most severe form of respiratory failure, acute respiratory distress syndrome (ARDS), are limited. This review focuses on the most promising therapies for ARDS, targeting different mechanisms that contribute to dysregulated inflammation and resultant hypoxemia. Significant heterogeneity exists within the ARDS population. Treatment requires prompt recognition of ARDS and an understanding of which patients may benefit most from specific pharmacologic interventions. The key to finding effective pharmacotherapies for ARDS may rely on deeper understanding of pathophysiology and bedside identification of ARDS subphenotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI